Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Boryung Blasts Into Space
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
You may also be interested in...
South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
South Korea’s healthcare services face both longer-term systemic challenges and short-term disruption from ongoing doctor walkouts over government plans to boost medical trainees. Meanwhile, the local pharma industry is calling for new measures to support the supply of essential drugs.